SANTA MONICA, Calif. and LAS VEGAS, July 20 - Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said its accomplishments in the first half of 2009 are the most significant in the Company's history and Cord Blood America is progressing to its goal of being the most important company in stem cell storage in the world.
January 6 - Launched the first social media campaign in the industry to start a public conversation about the potential usefulness of stem cells and the importance of storing umbilical cord blood stem cells.
January 9 - Established its three pillars of success for 2009: Organic growth, acquisitions and debt reduction leading to a healthy balance sheet.
February 9 - The Obama Administration announces its plan and support of stem cell research in the United States; Cord Blood America is listed on the ETF Innovators Stem Cell 40 company index.
February 12 - CBAI announces $1 million reduction in long term debt.
February 25 - CBAI announces restructuring of long term debt to free up cash flow for the company.
March 5 - CBAI noted as the top stock performer on ETF Innovators Stem Cell index, with a year-to-date stock price increase of 279 percent.
April 5 - Congress introduces legislation to promote Family Banking of Umbilical Cord Blood stem cells; CBAI announces its total long term debt reduction at $1.75 million.
April 9 - CBAI announces its first customer in Germany, noting its dedication to organic growth.
April 23 - CBAI announces additional debt reduction of $817,000.
May 7 - CBAI says it will acquire or build its own stem cell processing and storage laboratory, eliminating the need to outsource lab services and projecting a significant increase in gross profit once complete.
May 14 - CBAI announces it received a $2.3 million commitment to finance the building of its stem cell lab.
May 27 - CBAI announces debt has been reduced by $4.194 million in 2009.
June 11- CBAI announces additional expansion in Europe.
June 22 - CBAI announces contracting independent affiliate to sell services in Caribbean and Central America.
Since the end of the mid-point of 2009, Cord Blood America has further secured $7.5 million in long term equity financing for growth and acquisition opportunities; announced it has begun building the one of the largest stem cell labs in the U.S.; and announced hiring of an experienced, successful management team to manage its new laboratory.
"On January 6, 2009, the closing CBAI stock price was $0.0017. On July 10, 2009, the closing stock price was 0.0033, a 94% increase in 6 months of trading. That's not where we want to be, we are still very undervalued, and I understand that the day-to-day swings of our very liquid and volatile stock price cause some investor concern," said Matthew Schissler, Chairman and CEO. "I tell investors to take a snapshot of the last six months, not six hours. Micro cap stocks are perhaps not for the faint of heart. We believe we're building a very valuable company and this snapshot of the past six months shows our progress."
"In January, CBAI stated its mission is to lay the foundation for a much stronger healthier company by the end of 2009, which included organic growth, acquisition and debt reduction. As you can see by these highlights, we remain laser-focused on executing these strategies," Mr. Schissler said. "Because of our focus, we were able to raise significant funding to build a lab with the future growth opportunities it affords us. We are also pleased by the current support of stem cell research in Washington, D.C. and Congressional and state legislative focus on family stem cell banking legislation."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ``anticipate,'' ``believe,'' ``expect,'' ``future,'' ``intend,'' ``plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
http://www.cordblood-america.com/...ts-significant-2009-progress.html -----------
Keine Kauf Empfehlung!!
Das Warten ist die grausamste Vermengung von Hoffnung und Verzweiflung, durch die eine Seele gefoltert werden kann.
Devise: "Kaufen, wenn alle anderen verkaufen" |
Thread abonnieren
(19.35%)